logo

For the Inventor, By the Inventor

Eagleville, PA, United States of America

Kun Guo

This inventor holds 6 USPTO granted patents and 1 published patent application. Top assignees: Aventis Pharmaceuticals Inc., Adc Dsl Systems, Inc., Centelion Sas. Active years: 2005-2011.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kun Guo. Retrieved from https://idiyas.com/inventor/kun-guo-ntnazmnd

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6 

% Patents Active = 33.3

Average Co-Inventor Count = 3.6

ph-index = 1

Forward Citations = 8(Granted Patents)


Location History:

  • Irvine, CA (US) (2006 - 2007)
  • Norristown, PA (US) (2008)
  • Eagleville, PA (US) (2005 - 2011)

Company Filing History:

goldMedal3 out of 207 
 
Aventis Pharmaceuticals Inc.
 patents
silverMedal1 out of 126 
 
Adc Dsl Systems, Inc.
 patents
bronzeMedal1 out of 2 
 
Centelion Sas
 patents
4. 1 out of 390 
 
Sanofi-Aventis
 patents

Years Active: 2005-2011

Loading Chart...
6 patents (USPTO):Explore Patents
1. 7989584 - AKT nucleic acids, polypeptides, and uses thereof (2011-08-02),
2. 7662628 - Human Akt3 nucleic acid and uses thereof (2010-02-16),
3. 7332593 - Variants of TRAF2 which act as an inhibitor of TNF-alpha (TNFα) signaling pathway (2008-02-19),
4. 7170894 - Establishment of an end to end virtual connection (2007-01-30),
5. 6998475 - Variants of traf2 which act as an inhibitor of tnf-alpha (tnfα) signaling pathway (2006-02-14),
6. 6881555 - AKT nucleic acids, polypeptides, and uses thereof (2005-04-19),

Title: The Innovations of Kun Guo

Introduction

Kun Guo is a notable inventor based in Eagleville, Pennsylvania. He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic applications related to human Akt3 proteins.

Latest Patents

Kun Guo holds a total of six patents. His latest patents include innovations related to AKT nucleic acids and polypeptides. The first patent focuses on human Akt3 proteins and polypeptides, detailing isolated nucleic acids encoding human Akt3, vectors containing them, and their therapeutic uses, especially in gene therapy. The expression of Akt3 is noted to inhibit cell death associated with hypoxia, apoptosis, or necrosis. The second patent similarly relates to human Akt3 nucleic acids and their therapeutic applications.

Career Highlights

Throughout his career, Kun Guo has worked with prominent companies in the pharmaceutical industry, including Aventis Pharmaceuticals Inc. and Sanofi-Aventis. His work has contributed to advancements in medical therapies and biotechnology.

Collaborations

Kun Guo has collaborated with notable professionals in his field, including Marco Pagnoni and Kenneth Lyle Clark. These collaborations have likely enhanced his research and development efforts.

Conclusion

Kun Guo's innovative work in biotechnology, particularly regarding human Akt3 proteins, showcases his significant contributions to the field. His patents and collaborations reflect a commitment to advancing therapeutic applications that can improve human health.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…